NASDAQ:RAPT RAPT Therapeutics (RAPT) Stock Forecast, Price & News $20.35 +0.30 (+1.50%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$19.98▼$20.4850-Day Range$16.06▼$21.3452-Week Range$12.85▼$32.45Volume168,963 shsAverage Volume298,918 shsMarket Capitalization$699.02 millionP/E RatioN/ADividend YieldN/APrice Target$41.22 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability RAPT Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.6% Upside$41.22 Price TargetShort InterestBearish8.50% of Shares Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews Sentiment1.40Based on 3 Articles This WeekInsider TradingSelling Shares$242,500 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.18) to ($3.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector488th out of 1,012 stocksPharmaceutical Preparations Industry230th out of 495 stocks 3.5 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.22, RAPT Therapeutics has a forecasted upside of 102.6% from its current price of $20.35.Amount of Analyst CoverageRAPT Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.50% of the outstanding shares of RAPT Therapeutics have been sold short.Short Interest Ratio / Days to CoverRAPT Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in RAPT Therapeutics has recently increased by 2.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRAPT Therapeutics has received a 75.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for RAPT Therapeutics is -0.53. Previous Next 3.6 News and Social Media Coverage News SentimentRAPT Therapeutics has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for RAPT Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for RAPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have sold 410.80% more of their company's stock than they have bought. Specifically, they have bought $47,475.00 in company stock and sold $242,500.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of RAPT Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to decrease in the coming year, from ($3.18) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -7.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RAPT Therapeutics (NASDAQ:RAPT) StockRapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.Read More Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPT Stock News HeadlinesMay 25, 2023 | finance.yahoo.comRAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced CancersMay 18, 2023 | americanbankingnews.comBrokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Target Price at $41.22May 28, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.May 13, 2023 | msn.comHC Wainwright & Co. Maintains RAPT Therapeutics (RAPT) Buy RecommendationMay 13, 2023 | americanbankingnews.comHC Wainwright Trims RAPT Therapeutics (NASDAQ:RAPT) Target Price to $41.00May 12, 2023 | markets.businessinsider.comAnalyst Expectations for RAPT Therapeutics's FutureMay 11, 2023 | benzinga.comRAPT Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.May 11, 2023 | finanznachrichten.deRAPT Therapeutics, Inc.: RAPT Therapeutics Reports First Quarter 2023 Financial ResultsMay 28, 2023 | Stansberry Research (Ad)Why 2023 Could Kick Off a "Cash Frenzy" in StocksBut the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.May 11, 2023 | msn.comRecap: RAPT Therapeutics Q1 EarningsMay 11, 2023 | finance.yahoo.comRAPT Therapeutics Reports First Quarter 2023 Financial ResultsMay 3, 2023 | finance.yahoo.comRAPT Therapeutics Announces the Appointment of Michael Listgarten as General CounselApril 25, 2023 | americanbankingnews.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $41.44 Consensus Target Price from BrokeragesApril 21, 2023 | americanbankingnews.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider William Ho Sells 5,000 Shares of StockApril 19, 2023 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $16.77April 17, 2023 | msn.comPrometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market SessionApril 2, 2023 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Earns "Buy" Rating from HC WainwrightApril 1, 2023 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Shares Down 5.3% March 30, 2023 | seekingalpha.comRAPT Therapeutics: Potential Strong Upside AheadMarch 29, 2023 | finance.yahoo.comRAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe AsthmaMarch 29, 2023 | americanbankingnews.comBrokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $41.44March 26, 2023 | benzinga.comRAPT Therapeutics, Inc.: Company Investigated by the Portnoy Law FirmMarch 24, 2023 | americanbankingnews.comJPMorgan Chase & Co. Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $42.00March 24, 2023 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Stock Price Down 4.2% After Analyst DowngradeMarch 23, 2023 | americanbankingnews.comEquities Analysts Set Expectations for RAPT Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:RAPT)March 22, 2023 | seekingalpha.comRapt Therapeutics (RAPT) Investor Presentation -slideshowMarch 21, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn SituationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPT Company Calendar Last Earnings3/14/2023Today5/28/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RAPT CUSIPN/A CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees81Year Founded2015Price Target and Rating Average Stock Price Forecast$41.22 High Stock Price Forecast$48.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+102.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,840,000.00 Net MarginsN/A Pretax Margin-10,456.09% Return on Equity-43.24% Return on Assets-39.17% Debt Debt-to-Equity RatioN/A Current Ratio10.86 Quick Ratio10.86 Sales & Book Value Annual Sales$1.53 million Price / Sales456.88 Cash FlowN/A Price / Cash FlowN/A Book Value$6.42 per share Price / Book3.17Miscellaneous Outstanding Shares34,350,000Free Float32,456,000Market Cap$699.02 million OptionableNot Optionable Beta0.37 Social Links Key ExecutivesBrian Russell WongPresident, Chief Executive Officer & DirectorRodney K. B. YoungChief Financial Officer & SecretaryWilliam HoChief Medical OfficerDirk G. BrockstedtChief Scientific OfficerJim FarmerVice President-Clinical OperationsKey CompetitorsPureTech HealthNASDAQ:PRTCLyell ImmunopharmaNASDAQ:LYELArcturus TherapeuticsNASDAQ:ARCTBioXcel TherapeuticsNASDAQ:BTAIHarrow HealthNASDAQ:HROWView All CompetitorsInsiders & InstitutionsPutnam Investments LLCSold 893 shares on 5/22/2023Ownership: 0.061%JPMorgan Chase & Co.Bought 8,103 shares on 5/18/2023Ownership: 0.072%New York State Common Retirement FundSold 3,900 shares on 5/18/2023Ownership: 0.048%Geode Capital Management LLCBought 73,649 shares on 5/16/2023Ownership: 1.539%Jane Street Group LLCBought 44,458 shares on 5/16/2023Ownership: 0.129%View All Insider TransactionsView All Institutional Transactions RAPT Stock - Frequently Asked Questions Should I buy or sell RAPT Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT shares. View RAPT analyst ratings or view top-rated stocks. What is RAPT Therapeutics' stock price forecast for 2023? 8 brokers have issued twelve-month price objectives for RAPT Therapeutics' shares. Their RAPT share price forecasts range from $23.00 to $48.00. On average, they expect the company's stock price to reach $41.22 in the next twelve months. This suggests a possible upside of 102.6% from the stock's current price. View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts. How have RAPT shares performed in 2023? RAPT Therapeutics' stock was trading at $19.80 at the start of the year. Since then, RAPT stock has increased by 2.8% and is now trading at $20.35. View the best growth stocks for 2023 here. When is RAPT Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our RAPT earnings forecast. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03. What ETFs hold RAPT Therapeutics' stock? ETFs with the largest weight of RAPT Therapeutics (NASDAQ:RAPT) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Alger 35 ETF (ATFV), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Biotechnology ETF (IBB). What is Brian Wong's approval rating as RAPT Therapeutics' CEO? 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM). When did RAPT Therapeutics IPO? (RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO. What is RAPT Therapeutics' stock symbol? RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT." Who are RAPT Therapeutics' major shareholders? RAPT Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (13.00%), Price T Rowe Associates Inc. MD (9.67%), Perceptive Advisors LLC (6.67%), BlackRock Inc. (6.33%), State Street Corp (4.77%) and Great Point Partners LLC (3.95%). Insiders that own company stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho. View institutional ownership trends. How do I buy shares of RAPT Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RAPT Therapeutics' stock price today? One share of RAPT stock can currently be purchased for approximately $20.35. How much money does RAPT Therapeutics make? RAPT Therapeutics (NASDAQ:RAPT) has a market capitalization of $699.02 million and generates $1.53 million in revenue each year. The company earns $-83,840,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. How can I contact RAPT Therapeutics? RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rapt.com. The company can be reached via phone at (650) 489-9000 or via email at investors@rapt.com. This page (NASDAQ:RAPT) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.